Geneius Biotechnology is a T cell immunotherapy company focused on therapies for cancer. There is growing evidence for the potential of T cell immunotherapy for successful treatment of cancer patients. Our proprietary approach is distinct and unique from other T cell immunotherapy approaches and promotes the surveillance and destruction of cancer cells by the immune system. Through a transformative academic collaboration we are rapidly translating products from bench to bedside. We are currently developing products for both hematologic and solid cancers through our academic collaboration and expect to start clinical trials by the end of the year.

Pending regulatory approval, our products will be transferred to commercial manufacturing and clinical development programs for multicenter clinical studies. Geneius Biotechnology is privately financed. It operates a laboratory in Natick, Massachusetts (near Boston) and is expanding its network to commercialize T cell immunotherapy globally.